Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested Capital

Spyre Therapeutics (SYRE) Equity Average (2016 - 2025)

Spyre Therapeutics' Equity Average history spans 10 years, with the latest figure at $585.2 million for Q4 2025.

  • For Q4 2025, Equity Average rose 38.47% year-over-year to $585.2 million; the TTM value through Dec 2025 reached $585.2 million, up 38.47%, while the annual FY2025 figure was $616.5 million, 75.69% up from the prior year.
  • Equity Average reached $585.2 million in Q4 2025 per SYRE's latest filing, up from $455.4 million in the prior quarter.
  • In the past five years, Equity Average ranged from a high of $585.2 million in Q4 2025 to a low of -$226.4 million in Q3 2023.
  • Average Equity Average over 5 years is $182.5 million, with a median of $116.0 million recorded in 2021.
  • Peak YoY movement for Equity Average: crashed 398.44% in 2023, then soared 1476.85% in 2024.
  • A 5-year view of Equity Average shows it stood at $93.0 million in 2021, then crashed by 36.64% to $58.9 million in 2022, then crashed by 152.08% to -$30.7 million in 2023, then skyrocketed by 1476.85% to $422.6 million in 2024, then surged by 38.47% to $585.2 million in 2025.
  • Per Business Quant, the three most recent readings for SYRE's Equity Average are $585.2 million (Q4 2025), $455.4 million (Q3 2025), and $469.2 million (Q2 2025).